Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.63% | 14.59% | 14.17% | 5.10% | 1.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.89% | 52.35% | 39.24% | 25.69% | 13.43% |
| Operating Income | -51.89% | -52.35% | -39.24% | -25.69% | -13.43% |
| Income Before Tax | -64.77% | -65.35% | -41.65% | -18.88% | 0.31% |
| Income Tax Expenses | 3.13% | 58.57% | 82.81% | 13.16% | 11.11% |
| Earnings from Continuing Operations | -64.84% | -65.68% | -41.94% | -18.93% | 0.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.84% | -65.68% | -41.94% | -18.93% | 0.30% |
| EBIT | -51.89% | -52.35% | -39.24% | -25.69% | -13.43% |
| EBITDA | -52.01% | -52.39% | -39.12% | -25.44% | -13.18% |
| EPS Basic | -60.22% | -62.91% | -23.82% | 10.11% | 46.56% |
| Normalized Basic EPS | -59.32% | -61.63% | -22.97% | 10.58% | 46.26% |
| EPS Diluted | -60.22% | -62.91% | -23.82% | 10.11% | 46.56% |
| Normalized Diluted EPS | -59.32% | -61.63% | -22.97% | 10.58% | 46.26% |
| Average Basic Shares Outstanding | 2.96% | 1.57% | 9.50% | 21.95% | 53.68% |
| Average Diluted Shares Outstanding | 2.96% | 1.57% | 9.50% | 21.95% | 53.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |